What Longevity Medicine Actually Includes and What It Does Not

At Regen.MD, longevity medicine means a physician-led process built on measurable biology: metabolic and biomarker evaluation, targeting of modifiable risk, and selective use of orthobiologics or peptide medicine when the findings support it. It does not mean promised outcomes, an anti-aging protocol sold off a shelf, or a claim that any injection reverses aging. The distinction is not marketing hygiene; it determines what your plan can honestly be built to achieve.

This page sets out the boundary in both directions, because the term “longevity” is used loosely enough in 2026 that patients arrive with expectations no clinic can meet. It also sets out something patients are rarely shown: what the published evidence behind each of these tools actually says, who was enrolled in those studies, and — the part that matters most to the people who come here — who was screened out of them.

How we define longevity medicine

We start from the premise that aging is not one event. It is several biological processes running at different rates in the same person, which is why a plan aimed at healthspan has to be assembled from your measurements rather than from a template.

That framing has a practical consequence. If your presenting problem is joint pain that fluctuates with metabolic stress, the longevity work and the joint work are not separate programs; they are the same evaluation looked at from two angles.

What it includes

• Metabolic and biomarker evaluation — a structured audit of your labs and how they move over time, used to choose targets rather than to confirm a preset plan.
• Mitochondrial and cellular energy education — how energy production relates to fatigue, recovery, and training tolerance, and where that changes sequencing.
• Inflammation biology — including how modern diet patterns relate to systemic and neuroinflammation, where that is relevant to your findings.
• Orthobiologics — intra-articular and tendon platelet-rich plasma, intraosseous and subchondral PRP, bone marrow aspirate concentrate, Lipogems, and intradiscal orthobiologics, for specific joint and tendon targets.
• Peptide and longevity medicine — discussed as clinical and educational subjects within a lab-driven plan.

What it does not include

• Any promise that a program stops or reverses aging.
• Any claim that an orthobiologic rebuilds a degenerated joint or restores lost cartilage to its original structure.
• Any assurance that care will never need to escalate if symptoms or function worsen.
• A single protocol applied to everyone, since the same intervention does not behave the same way in two different metabolic terrains.
• Peptides sold as a product. They are a clinical and educational subject here, not merchandise.

How to read the evidence behind a longevity claim

Almost every public disagreement about longevity medicine is really a disagreement about evidence: what counts, how strong it is, and to whom it applies. Three distinctions do most of the work, and we use them openly in the evaluation rather than presenting a study as settled when it is not.

Who a trial enrolled is part of what the trial found

Randomized trials earn their authority by controlling who enters them. That same control is a limit: the eligibility list decides which humans the result describes. Trials in this field routinely exclude obesity above a stated threshold, poorly controlled diabetes, systemic inflammatory and autoimmune disease, anticoagulation, immunosuppression, recent cancer, and previous treatment with the therapy under study — which is to say, several of the features that bring people to a metabolic and regenerative practice in the first place.

A modest or null result in a screened population is a real finding about that population, and we report it as one. It is not evidence that the same intervention fails in patients who would not have qualified for the trial. Reading it that way is an error in both directions: it can make a useful treatment look worthless, and it can make a treatment tested only in healthy volunteers look safer than it is in someone with metabolic disease.

Efficacy under trial conditions is not effectiveness in a clinic

Trials usually test one thing at a time, on a fixed schedule, for a fixed period, against a single outcome measure. Care is sequenced and combined, adjusted to response, and carried on past the twelve-month mark where most trials stop. A single-modality trial cannot measure what a combination does, and short follow-up cannot measure durability.

That argument cuts in every direction. It is a reason not to dismiss a therapy on one negative trial, and equally a reason not to claim a benefit that no trial has measured. Where we rely on it, we say so.

Most longevity markers are associations, not levers

Cardiorespiratory fitness, grip strength, and telomere length are all associated with how long people live. Nearly all of that evidence comes from observational cohorts, which can show that a marker tracks with risk but cannot show that moving the marker moves the risk. Those cohorts also enroll general populations, not clinic populations, so the numbers describe a different group of people than the one sitting in the room.

That is not a reason to ignore the markers. It is a reason to label them accurately, which is what the rest of this page tries to do.

Biological aging frameworks, and what we actually do with them

Part of the confusion is that “longevity” can refer to several different biological models at once. Concepts such as telomere biology and gene expression are useful for explaining why a plan is sequenced the way it is; they are not shortcuts to a treatment decision.

We treat them as educational scaffolding. When you read about an aging biomarker, the honest position is that the translation from that marker to a specific clinical action is often not established, and we will say when that is the case rather than manufacturing a protocol around it.

What the fitness and strength data show, and what they do not

In a retrospective cohort of 122,007 adults referred for exercise treadmill testing at one United States health system between 1991 and 2014, cardiorespiratory fitness was inversely associated with long-term mortality: 13,637 deaths occurred over a median 8.4 years of follow-up, and adults in the elite fitness group had an adjusted hazard ratio of 0.20 (95% CI, 0.16–0.24) for all-cause mortality compared with the lowest-performing quartile. The authors observed no upper limit of benefit [1].

That is an observational cohort of people referred for a stress test, not a random sample and not a trial. Adults undergoing pharmacologic stress testing and those unable to reach 85% of maximum predicted heart rate were excluded, which by design removes many of the least fit and most medically complex patients from the analysis [1].

Grip strength shows the same pattern in a very different population. Among 139,691 adults in the Prospective Urban Rural Epidemiology study, drawn from households in 17 countries with at least one member aged 35 to 70, each 5 kg lower grip strength was associated with a hazard ratio of 1.16 (95% CI, 1.13–1.20) for all-cause mortality and 1.17 (95% CI, 1.11–1.24) for cardiovascular mortality over a median 4.0 years, making grip strength a stronger predictor of those outcomes than systolic blood pressure. There was no significant association with incident diabetes, fall injury, or fracture [2].

The PURE investigators stated plainly that further research is needed to test whether improving strength reduces mortality and cardiovascular disease [2]. We hold the same position. Fitness and strength stay in the plan because they are modifiable, measurable, and repeatedly associated with outcome — not because a trial has shown that raising them extends life.

Telomeres, and why longer is not simply better

Telomere length is the most heavily promoted aging biomarker and the clearest illustration of why a marker is not automatically a target. A Mendelian randomization analysis covering 35 cancers and 48 non-neoplastic diseases, with 420,081 cases and 1,093,105 controls, found that genetically longer telomeres were associated with higher risk of several cancers — glioma, odds ratio 5.27 (95% CI, 3.15–8.81); lung adenocarcinoma, 3.19 (95% CI, 2.40–4.22); melanoma, 1.87 (95% CI, 1.55–2.26) — and with lower risk of coronary heart disease, 0.78 (95% CI, 0.67–0.90), and abdominal aortic aneurysm, 0.63 (95% CI, 0.49–0.81) [3].

That analysis examined telomere length set by inherited genetic variation. It was not a trial of lengthening telomeres, and no such intervention is offered here. The finding stands on its own for our purposes: the direction of benefit is not the same for every disease, so “longer telomeres” cannot serve as a treatment goal. We use telomere biology to explain sequencing, and we do not build a protocol around it.

The metabolic audit: the part you can measure

If you want the most concrete answer to what longevity medicine includes here, it is the metabolic audit. This is biomarker assessment plus trend monitoring, used to pick targets and then to check whether the targets are moving.

The audit also does something the published literature cannot do for you. Because trials repeatedly screen out uncontrolled diabetes, high body mass index, autoimmune disease, and anticoagulation, the studies that inform a treatment decision were often run in people whose metabolic terrain is nothing like yours. Measuring your terrain is how we work out which published results are likely to apply to you and which are not.

What a metabolic audit does not do

• It does not replace diagnosis. If something needs standard medical evaluation, it still needs standard medical evaluation.
• It does not assure symptom relief. It tells us what to aim at and whether we are hitting it.
• It is not a test that proves anything about how long you will live. It is a decision tool.

That measurement discipline matters most when joint pain tracks with metabolic stress, because in those cases treating the joint alone tends to produce short-lived results.

Where orthobiologics fit, and where they stop

Many people arrive at longevity medicine through a joint problem, usually a knee, and usually after being told surgery is the next step. Orthobiologics are one domain inside the larger plan, and this is where the boundary matters most.

We offer intra-articular and tendon PRP, intraosseous and subchondral PRP, bone marrow aspirate concentrate, Lipogems, and intradiscal orthobiologics. In advanced knee osteoarthritis, PRP is framed as a safe bridge therapy prior to arthroplasty. We make no claim that any of these restores lost cartilage.

The largest placebo-controlled PRP trial, and what it found

The RESTORE trial randomized 288 community-recruited adults (mean age 61.9 years, 59% female) with symptomatic mild-to-moderate medial knee osteoarthritis to three weekly intra-articular injections of leukocyte-poor PRP or saline placebo, at two radiology centers in Sydney and Melbourne between August 2017 and July 2020; 269 participants (93%) completed the study [4].

It was negative. At 12 months, knee pain fell 2.1 points in the PRP group and 1.8 points in the placebo group, a difference of −0.4 (95% CI, −0.9 to 0.2; P = .17) against a minimal clinically important difference of 1.8 points. Medial tibial cartilage volume fell 1.4% with PRP and 1.2% with placebo, a difference of −0.2% (95% CI, −1.9% to 1.5%; P = .81). Of 31 secondary outcomes, only global improvement at 2 months favored PRP [4]. That is what the trial found, and nothing below reverses it.

Whom RESTORE screened out

The published protocol lists 22 exclusion criteria. Participants were excluded if they had Kellgren-Lawrence grade 1 or grade 4 disease, lateral joint space narrowing greater than or equal to medial, a glucocorticoid injection in the past 3 months or hyaluronic acid in the past 6 months, any autologous blood product or stem cell preparation at any time in the past, knee surgery on the target knee within 12 months, systemic or inflammatory joint disease such as rheumatoid arthritis, a history of crystalline or neuropathic arthropathy, a prior knee replacement or high tibial osteotomy, or a plan for joint surgery in the next 12 months [5].

The list continues: other muscular, joint or neurological conditions affecting lower limb function; needle phobia; immunosuppression or acute infective processes; cancer or other tumors, or treatment for them, in the last 3 years; a bleeding disorder or anticoagulation therapy; a warm, tense joint effusion; a platelet count below 150,000/µL; contraindications to MRI; pregnancy; unwillingness to discontinue non-steroidal anti-inflammatory drugs for the duration; and a body mass index above 40 kg/m², which the protocol attributes to fitting the MRI knee coil rather than to any clinical judgment [5].

Read that list against a regenerative clinic’s waiting room. Grade 4 disease — the severe end — was excluded. So was anyone who had already tried an autologous blood product and come back. So was systemic inflammatory disease, immunosuppression, anticoagulation, a low platelet count, and obesity past a threshold. RESTORE is strong evidence about three weekly leukocyte-poor PRP injections, given alone, over twelve months, in adults with grade 2 or 3 medial knee osteoarthritis and no inflammatory or hematologic complication. It was not designed to answer any other question, and it does not.

What has accumulated since, and where it is unsettled

A 2025 meta-analysis of 18 randomized controlled trials comparing PRP with placebo injections in knee osteoarthritis, covering 1,995 patients (1,047 PRP, 948 control) across Kellgren-Lawrence grades 1 to 4, reported clinically relevant functional improvement on the WOMAC index at 1, 3, 6, and 12 months and pain relief exceeding the minimal clinically important difference on a visual analog scale at 3 and 6 months [6].

The same analysis found that platelet concentration influenced the result. Using a cutoff of 1,000,000 ± 20% platelets/µL, high-platelet preparations exceeded the pain threshold at 3, 6, and 12 months, while low-platelet preparations did not deliver clinically perceivable pain benefit at any timepoint [6]. RESTORE used a leukocyte-poor preparation [4]; the meta-analysis authors note that trials in this field differ in blood volume drawn, anticoagulant, number and speed of centrifugations, final volume, leukocyte content, platelet number and activation method, and they describe this as considerable heterogeneity in the field, along with a limited number of studies supporting each subanalysis [6].

This is what a genuinely unsettled question looks like, and it should be described as unsettled rather than resolved in either direction. A pooled estimate across heterogeneous preparations does not overturn a well-conducted negative trial, and a single negative trial of one preparation does not settle a literature in which the preparation itself appears to change the answer.

The severe-disease population the trials usually exclude

One randomized trial went looking specifically at the population RESTORE screened out. A double-blind, multicenter trial at two Spanish public hospitals randomized 86 patients aged 40 to 75 with Kellgren-Lawrence grade III–IV knee osteoarthritis, at least six months of moderate-to-severe symptoms, and no response to other pharmacological treatment. Everyone received three intra-articular injections of plasma rich in growth factors; the randomized comparison was whether the first session also included an intraosseous injection of the same preparation or of saline [7].

Both groups improved significantly from baseline on all KOOS and WOMAC subscales at 3, 6, and 12 months. The group that received the intraosseous injection improved significantly more in nearly all domains — pain, symptoms, function, and quality of life — at every timepoint. No serious adverse events were recorded; 15 patients, 7 in one group and 8 in the other, reported pain and swelling in the first 72 hours that resolved on its own. Two patients, one from each group, left the study to undergo knee replacement [7].

This trial has its own eligibility boundary, and it is close to the one that matters here: it excluded body mass index of 35 or above, poorly controlled hypertension or diabetes, systemic autoimmune disease or immunosuppressive treatment, active oncological treatment or follow-up, and anticoagulant or antiplatelet therapy that could not be paused [7]. It should also be read knowing that three of its authors are affiliated with the biotechnology company behind the preparation studied, which the paper discloses [7].

Alongside it sits a retrospective survival analysis of 667 patients treated with PRP at a single Spanish center, in which 74.1% of those who eventually had a knee replacement had delayed it by more than 1.5 years, with a median delay of 5.3 years, and 85.7% had not undergone replacement within five years of treatment. That study had no control group, no randomization, and no way to know what those same patients would have done untreated; its own authors concluded only that PRP could delay replacement and that further study is needed [8].

Taken together, that is the honest basis for the position stated above. In advanced knee osteoarthritis, PRP is offered as a safe bridge therapy prior to arthroplasty — a way to buy function and time in a joint that already has structural disease, in a patient for whom surgery is on the table. It is not offered as a way to avoid an operation that has become necessary, and it is not offered as structural repair.

What orthobiologics do not do

• They do not assure that joint or tendon pain resolves.
• They do not assure that surgery will never be needed.
• They do not act on aging as a whole. They act on a tissue target that has been identified.
• They do not perform identically across preparations. Platelet concentration, leukocyte content, and delivery route all appear to matter, and the field has not standardized any of them [6].

Peptides, muscle loss, and the limits of the conversation

Peptide therapy is the area where expectations most often outrun the evidence. Here it is a physician-directed clinical and educational subject, framed within lab-driven protocols, and it is not something you purchase from a menu.

Sarcopenia is the practical version of this discussion for most patients, because muscle loss determines mobility and independence long before anything else does. Peptides may be part of a preservation strategy when clinically appropriate, but they are not presented as a standalone answer to age-related muscle loss, and loading, protein intake, and metabolic control remain the foundation. The evidence below is a large part of why we hold that line.

What two years on the growth hormone axis actually produced

The longest randomized data on stimulating the growth hormone axis in older adults comes from a two-year, double-blind, placebo-controlled trial of an oral ghrelin mimetic in 65 healthy adults aged 60 to 81. Fat-free mass rose 1.1 kg (95% CI, 0.7 to 1.5) in the treated group and fell 0.5 kg (95% CI, −1.1 to 0.2) on placebo, a significant difference; body weight rose 2.7 kg versus 0.8 kg [9].

Strength and function did not follow. The investigators reported no significant between-group changes in total work in knee extension or flexion or in shoulder extension, and no significant changes in any measurement of function. Fasting blood glucose rose an average of 5 mg/dL, hemoglobin A1c rose 0.2%, and insulin sensitivity declined [9]. That last cluster is the part a metabolic practice has to take seriously.

Note who was in that trial: healthy adults, screened to rule out underlying disease. Diabetes was an exclusion. So were body mass index of 35 or above, untreated hypertension, thyroid disease, smoking, and any medication affecting growth hormone secretion [9]. So the trial neither proves nor refutes anything about a patient with established insulin resistance — but the direction of its metabolic signal, observed in people selected for metabolic health, is a reason for more caution in that patient, not less. The compound studied is not a peptide and is not used here; it is cited because it is the cleanest long-term test of the mechanism that growth hormone secretagogue peptides are discussed on.

Why loading stays the foundation

The comparison case is instructive. In a randomized trial of 100 frail nursing home residents with a mean age of 87.1 years (range 72 to 98), ten weeks of progressive resistance training increased muscle strength by 113% ± 8% against 3% ± 9% in non-exercising participants, increased gait velocity by 11.8% ± 3.8% against a 1.0% decline, and increased stair-climbing power by 28.4% ± 6.6% against 3.6% ± 6.7%. A multinutrient supplement without exercise had no effect on any primary outcome [10].

That study ran for ten weeks in the frailest population available, so it says nothing directly about a 55-year-old and nothing about durability past ten weeks. What it does establish is that mechanical loading was still producing large functional gains at 87 years of age, in exactly the patients most trials exclude, while a supplement given without loading produced none. Any conversation about peptides and muscle that skips past that finding has the sequence backwards.

How risk, benefit, and coverage are actually discussed

The evaluation is where all of this gets applied to one person. For any intervention under consideration, the discussion covers what the evidence shows, whom that evidence was drawn from, whether you resemble that group, what is genuinely unknown, what the plausible harms are, and what would make us stop or change course.

Where a treatment has been tested mainly in people unlike you, we say so and treat the plan as a monitored trial of one with defined checkpoints, rather than as a settled protocol. Where the evidence is strong, we say that too. The goal is that you can repeat back, in your own words, what is known and what is not before anything is scheduled.

Insurance is a separate conversation and belongs in a separate box. Whether a payer covers a service is a coverage and reimbursement decision made by that payer; it is not a finding about whether the treatment works, and it never functions as clinical evidence in either direction. For services a payer does not cover, patients sign an advance beneficiary notice acknowledging that before anything proceeds, so the financial picture is settled in writing ahead of care rather than discovered afterward.

“My ethos is to treat all of my patients as I would my own family, with the goal of giving them back their quality of life.” — Dr. Gurpreet Singh Padda, MD, MBA, MHP

Conservative first, and what happens when conservative care runs out

Care begins with a paid, physician-led Clinical Evaluation with Dr. Gurpreet Singh Padda, MD, MBA, MHP, after which a plan is built against the findings rather than against a package.

We sequence conservative measures first whenever that is clinically reasonable. When conservative care has genuinely been exhausted, surgery is a legitimate next step and it is available here — Dr. Padda is a surgeon. What we do not do is present surgery as the opening move, or present a biologic injection as a way to avoid a decision that has already become necessary.

The clinic is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport; details are on our St. Louis clinic page.

Frequently Asked Questions

Sources

1. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. “Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing.” JAMA Network Open, 2018;1(6):e183605. https://doi.org/10.1001/jamanetworkopen.2018.3605 — referenced for the 122,007-adult retrospective cohort, the 13,637 deaths over a median 8.4 years, and the adjusted hazard ratio of 0.20 (95% CI, 0.16–0.24) for elite versus low cardiorespiratory fitness.
2. Leong DP, Teo KK, Rangarajan S, et al. “Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study.” The Lancet, 2015;386(9990):266–273. https://doi.org/10.1016/S0140-6736(14)62000-6 — referenced for the 139,691 participants across 17 countries, the hazard ratios per 5 kg lower grip strength, the comparison with systolic blood pressure, and the authors’ statement that further research is needed to test whether improving strength reduces mortality.
3. Telomeres Mendelian Randomization Collaboration; Haycock PC, Burgess S, Nounu A, et al. “Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.” JAMA Oncology, 2017;3(5):636–651. https://doi.org/10.1001/jamaoncol.2016.5945 — referenced for the 35 cancers and 48 non-neoplastic diseases analyzed, the 420,081 cases and 1,093,105 controls, and the odds ratios for glioma, lung adenocarcinoma, melanoma, coronary heart disease, and abdominal aortic aneurysm.
4. Bennell KL, Paterson KL, Metcalf BR, et al. “Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.” JAMA, 2021;326(20):2021–2030. https://doi.org/10.1001/jama.2021.19415 — referenced for the 288 participants, the leukocyte-poor preparation, the 12-month pain and cartilage-volume results with confidence intervals, and the secondary-outcome findings.
5. Paterson KL, Hunter DJ, Metcalf BR, et al. “Efficacy of intra-articular injections of platelet-rich plasma as a symptom- and disease-modifying treatment for knee osteoarthritis — the RESTORE trial protocol.” BMC Musculoskeletal Disorders, 2018;19:272. https://doi.org/10.1186/s12891-018-2205-5 — referenced for the trial’s four inclusion criteria and its 22 exclusion criteria as published, including the grade 4 exclusion and the stated reason for the body mass index limit.
6. Bensa A, Previtali D, Sangiorgio A, Boffa A, Salerno M, Filardo G. “PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials.” The American Journal of Sports Medicine, 2025;53(3):745–754. https://doi.org/10.1177/03635465241246524 — referenced for the 18 trials and 1,995 patients, the WOMAC and visual analog scale results against their minimal clinically important differences, the 1,000,000 ± 20% platelets/µL subanalysis, and the authors’ account of preparation heterogeneity.
7. Sánchez Santiuste M, Vaquerizo García V, Pareja Esteban JA, Prado R, Padilla S, Anitua E. “Plasma Rich in Growth Factors (PRGF) Versus Saline Intraosseous Infiltrations Combined with Intra-Articular PRGF in Severe Knee Osteoarthritis: A Prospective Double-Blind Multicentric Randomized Controlled Trial with 1-Year Follow-Up.” Journal of Clinical Medicine, 2025;14(22):8075. https://doi.org/10.3390/jcm14228075 — referenced for the 86 randomized patients with Kellgren-Lawrence grade III–IV disease, the inclusion and exclusion criteria, the KOOS and WOMAC results, the adverse-event record, and the authors’ disclosed affiliation with the manufacturer of the preparation studied.
8. Sánchez M, Jorquera C, Sánchez P, Beitia M, García-Cano B, Guadilla J, Delgado D. “Platelet-rich plasma injections delay the need for knee arthroplasty: a retrospective study and survival analysis.” International Orthopaedics, 2021;45(2):401–410. https://doi.org/10.1007/s00264-020-04669-9 — referenced for the 667 patients meeting inclusion criteria, the 74.1% who delayed replacement by more than 1.5 years, the median 5.3-year delay, the 85.7% five-year figure, and the authors’ own call for further study.
9. Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Annals of Internal Medicine, 2008;149(9):601–611. https://doi.org/10.7326/0003-4819-149-9-200811040-00003 — referenced for the 65 healthy adults aged 60 to 81, the fat-free mass and body weight results, the absence of strength and function changes, the fasting glucose and hemoglobin A1c changes, and the exclusion criteria.
10. Fiatarone MA, O’Neill EF, Ryan ND, et al. “Exercise training and nutritional supplementation for physical frailty in very elderly people.” The New England Journal of Medicine, 1994;330(25):1769–1775. https://doi.org/10.1056/NEJM199406233302501 — referenced for the 100 frail nursing home residents of mean age 87.1 years, the strength, gait velocity and stair-climbing power results, and the finding that the multinutrient supplement alone had no effect on any primary outcome.
11. Regen.MD, “Orthobiologics — Intraosseous & Subchondral PRP, BMAC, Failed PRP Revision,” https://regen.md/services/orthobiologics/ — referenced for the orthobiologic procedures this practice performs.
12. Regen.MD, “Physician-Directed Peptide Therapy — Lab-Driven Protocols,” https://regen.md/services/peptide-therapy/ — referenced for the physician-directed, lab-driven framing of peptide medicine and for the fact that peptides are not sold as a product.
13. Regen.MD, “Biological Aging, Telomeres & Gene Expression,” https://regen.md/biological-aging-telomeres-gene-expression/ — referenced for the biological-aging concepts used as educational scaffolding.
14. Regen.MD, “The Metabolic Audit: Can Your Body Heal?,” https://regen.md/metabolic-audit-biomarkers/ — referenced for the metabolic audit and biomarker-trend monitoring described above.
15. Regen.MD, “Mitochondrial Dysfunction and Healing,” https://regen.md/mitochondrial-dysfunction-cellular-energy/ — referenced for the mitochondrial and cellular-energy material.
16. Regen.MD, “Brain Inflammation & the Modern Diet,” https://regen.md/brain-inflammation-metaflammation/ — referenced for the inflammation and diet material.
17. Regen.MD, “Muscle Loss and Aging: Sarcopenia,” https://regen.md/muscle-loss-aging-sarcopenia-peptides/ — referenced for the sarcopenia material.
18. Regen.MD, “Our Approach,” https://regen.md/our-approach/ — referenced for the Clinical Evaluation process and conservative-first sequencing.

Note on sources: entries 1 through 10 are primary literature that was read for this page; each statistic in the body is attributed inline to the numbered entry it came from, and the population that statistic describes is named alongside it. Entries 11 through 18 are this practice’s own clinical and educational pages, cited only for statements about what this practice does and how it sequences care. No figure appears in this article without a source in this list.